Membranolytic anticancer peptides (ACPs) are drawing increasing attention as potential future therapeutics against cancer, due to their ability to hinder the development of cellular resistance and their potential to overcome common hurdles of chemotherapy, e.g., side effects and cytotoxicity. In this work, we present an ensemble machine learning model to design potent ACPs. Four counter-propagation artificial neural-networks were trained to identify peptides that kill breast and/or lung cancer cells. For prospective application of the ensemble model, we selected 14 peptides from a total of 1000 de novo designs, for synthesis and testing in vitro on breast cancer (MCF7) and lung cancer (A549) cell lines. Six de novo designs showed anticancer activity in vitro, five of which against both MCF7 and A549 cell lines. The novel active peptides populate uncharted regions of ACP sequence space.
This is a preview of subscription content, access via your institution.
Buy single article
Instant access to the full article PDF.
Tax calculation will be finalised during checkout.
Subscribe to journal
Immediate online access to all issues from 2019. Subscription will auto renew annually.
Tax calculation will be finalised during checkout.
Gabernet G, Müller AT, Hiss JA, Schneider G (2016) Membranolytic anticancer peptides. Med Chem Commun 7:2232–2245. https://doi.org/10.1039/C6MD00376A
Papo N, Shai Y (2005) Host defense peptides as new weapons in cancer treatment. Cell Mol Life Sci 62:784–790. https://doi.org/10.1007/s00018-005-4560-2
Mader JS, Hoskin DW (2006) Cationic antimicrobial peptides as novel cytotoxic agents for cancer treatment. Expert Opin Investig Drugs 15:933–946. https://doi.org/10.1517/135437188.8.131.523
Hoskin DW, Ramamoorthy A (2008) Studies on anticancer activities of antimicrobial peptides. Biochim Biophys Acta 1778:357–375. https://doi.org/10.1016/j.bbamem.2007.11.008
Riedl S, Zweytick D, Lohner K (2011) Membrane-active host defense peptides – challenges and perspectives for the development of novel anticancer drugs. Chem Phys Lipids 164:766–781. https://doi.org/10.1016/j.chemphyslip.2011.09.004
Dennison SR, Whittaker M, Harris F, Phoenix DA (2006) Anticancer α-helical peptides and structure/function relationships underpinning their interactions with tumour cell membranes. Curr Protein Pept Sci 7:487–499
Gaspar D, Veiga AS, Castanho MARB (2013) From antimicrobial to anticancer peptides. A review. Front Microbiol 4:294. https://doi.org/10.3389/fmicb.2013.00294
Fosgerau K, Hoffmann T (2015) Peptide therapeutics: current status and future directions. Drug Discov Today 20:122–128. https://doi.org/10.1016/j.drudis.2014.10.003
Wang G, Li X, Wang Z (2016) APD3: the antimicrobial peptide database as a tool for research and education. Nucleic Acids Res 44:D1087–D1093. https://doi.org/10.1093/nar/gkv1278
Shoombuatong W, Schaduangrat N, Nantasenamat C (2018) Unraveling the bioactivity of anticancer peptides as deduced from machine learning. EXCLI J 17:734. https://doi.org/10.17179/excli2018-1447
Tyagi A, Tuknait A, Anand P et al (2015) CancerPPD: a database of anticancer peptides and proteins. Nucleic Acids Res 43:D837–D843. https://doi.org/10.1093/nar/gku892
(2018) Cancer Facts & Figures 2018 | American Cancer Society. https://www.cancer.org/research/cancer-facts-statistics/all-cancer-facts-figures/cancer-facts-figures-2018.html. Accessed 11 Nov 2018
Siegel RL, Miller KD, Jemal A (2018) Cancer statistics, 2018. CA Cancer J Clin 68:7–30. https://doi.org/10.3322/caac.21442
Grisoni F, Neuhaus CS, Gabernet G et al (2018) Designing anticancer peptides by constructive machine learning. ChemMedChem 13:1300–1302. https://doi.org/10.1002/cmdc.201800204
Merk D, Friedrich L, Grisoni F, Schneider G (2018) De novo design of bioactive small molecules by artificial intelligence. Mol Inf 37:1700153. https://doi.org/10.1002/minf.201700153
Tyagi A, Kapoor P, Kumar R et al (2013) In silico models for designing and discovering novel anticancer peptides. Sci Rep 3:2984. https://doi.org/10.1038/srep02984
Hajisharifi Z, Piryaiee M, Mohammad Beigi M et al (2014) Predicting anticancer peptides with Chou′s Pseudo amino acid composition and investigating their mutagenicity via Ames test. J Theor Biol 341:34–40. https://doi.org/10.1016/j.jtbi.2013.08.037
Vijayakumar S, PTV L (2015) ACPP: a web server for prediction and design of anti-cancer peptides. Int J Pept Res Ther 21:99–106. https://doi.org/10.1007/s10989-014-9435-7
Chen W, Ding H, Feng P et al (2016) iACP: a sequence-based tool for identifying anticancer peptides. Oncotarget 7:16895–16909. https://doi.org/10.18632/oncotarget.7815
Manavalan B, Basith S, Shin TH et al (2017) MLACP: machine-learning-based prediction of anticancer peptides. Oncotarget 8:77121–77136. https://doi.org/10.18632/oncotarget.20365
Xu L, Liang G, Wang L et al (2018) A novel hybrid sequence-based model for identifying anticancer peptides. Genes 9:158. https://doi.org/10.3390/genes9030158
Akbar S, Hayat M, Iqbal M, Jan MA (2017) iACP-GAEnsC: evolutionary genetic algorithm based ensemble classification of anticancer peptides by utilizing hybrid feature space. Artif Intell Med 79:62–70. https://doi.org/10.1016/j.artmed.2017.06.008
Hecht-Nielsen R (1987) Counterpropagation networks. Appl Opt 26:4979–4984. https://doi.org/10.1364/AO.26.004979
(2018) Cancer. In: World Health Organ. http://www.who.int/news-room/fact-sheets/detail/cancer. Accessed 12 Nov 2018
Koch CP, Perna AM, Pillong M et al (2013) Scrutinizing MHC-I binding peptides and their limits of variation. PLoS Comput Biol 9:e1003088
Müller AT, Gabernet G, Hiss JA, Schneider G (2017) modlAMP: python for antimicrobial peptides. Bioinformatics 33:2753–2755. https://doi.org/10.1093/bioinformatics/btx285
Kruskal JB (1964) Nonmetric multidimensional scaling: a numerical method. Psychometrika 29:115–129. https://doi.org/10.1007/BF02289694
Ballabio D, Grisoni F, Todeschini R (2018) Multivariate comparison of classification performance measures. Chemom Intell Lab Syst 174:33–44. https://doi.org/10.1016/j.chemolab.2017.12.004
Brown JB (2018) Classifiers and their metrics quantified. Mol Inf 37:1700127. https://doi.org/10.1002/minf.201700127
Zupan J, Novič M, Ruisánchez I (1997) Kohonen and counterpropagation artificial neural networks in analytical chemistry. Chemom Intell Lab Syst 38:1–23. https://doi.org/10.1016/S0169-7439(97)00030-0
Kohonen T (2012) Self-organization and associative memory. Springer, Berlin. https://doi.org/10.1007/978-3-642-88163-3
Goldberg DE, Holland JH (1988) Genetic algorithms and machine learning. Mach Learn 3:95–99. https://doi.org/10.1023/A:1022602019183
Ballabio D, Vasighi M, Consonni V, Kompany-Zareh M (2011) Genetic algorithms for architecture optimisation of counter-propagation artificial neural networks. Chemom Intell Lab Syst 105:56–64. https://doi.org/10.1016/j.chemolab.2010.10.010
Ballabio D, Consonni V, Todeschini R (2009) The Kohonen and CP-ANN toolbox: a collection of MATLAB modules for self organizing maps and counterpropagation artificial neural networks. Chemom Intell Lab Syst 98:115–122. https://doi.org/10.1016/j.chemolab.2009.05.007
Merrifield RB (1963) Solid phase peptide synthesis. I. The synthesis of a tetrapeptide. J Am Chem Soc 85:2149–2154. https://doi.org/10.1021/ja00897a025
Breiman L (1996) Bagging predictors. Mach Learn 24:123–140. https://doi.org/10.1007/BF00058655
Guo X, Ma C, Du Q et al (2013) Two peptides, TsAP-1 and TsAP-2, from the venom of the Brazilian yellow scorpion, Tityus Serrulatus: evaluation of their antimicrobial and anticancer activities. Biochimie 95:1784–1794. https://doi.org/10.1016/j.biochi.2013.06.003
Baker MA, Maloy WL, Zasloff M, Jacob LS (1993) Anticancer efficacy of Magainin2 and analogue peptides. Cancer Res 53:3052–3057
Usmani SS, Bedi G, Samuel JS et al (2017) THPdb: database of FDA-approved peptide and protein therapeutics. PLoS One 12:e0181748. https://doi.org/10.1371/journal.pone.0181748
Schneider G, Neidhart W, Giller T, Schmid G (1999) “Scaffold-hopping” by topological pharmacophore search: a contribution to virtual screening. Angew Chem Int Ed 38:2894–2896. https://doi.org/10.1002/(SICI)1521-3773(19991004)38:19<2894::AID-ANIE2894>3.0.CO;2-F
The authors thank Sarah Haller for technical support. This research was financially supported by the Swiss National Science Foundation (grants no. CRSII2_160699, no. 200021_157190 and no. IZSEZ0_177477). M.H. was financially supported by “Tobitate! (Leap for tomorrow)” study abroad initiative (Japan’s Ministry of Education, Culture, Sports, Science, and Technology [MEXT]).
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
This paper belongs to the Topical Collection Tim Clark 70th Birthday Festschrift
About this article
Cite this article
Grisoni, F., Neuhaus, C.S., Hishinuma, M. et al. De novo design of anticancer peptides by ensemble artificial neural networks. J Mol Model 25, 112 (2019). https://doi.org/10.1007/s00894-019-4007-6
- Artificial intelligence
- Machine learning
- Peptide design